Are you Dr. Ferrajoli?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 52 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161
Summary
- Dr. Alessandra Ferrajoli, MD is an oncologist in Houston, Texas. She is currently licensed to practice medicine in Texas, Florida, and Oklahoma. She is affiliated with University of Texas M.D. Anderson Cancer Center.
Education & Training
University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 1998 - 2001- University of Texas Health Science Center at HoustonResidency, Internal Medicine, 1995 - 1998
University of Perugia Faculty of MedicineClass of 1988
Certifications & Licensure
FL State Medical License 2021 - Present
TX State Medical License 2000 - 2026
OK State Medical License 2020 - 2021- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Campath-1H Plus Rituximab for CD52- and CD20- Positive Refractory or Relapsed Chronic Lymphoid Disorders Start of enrollment: 2002 Oct 01
- Continuous Infusion of Campath-1H Followed by Subcutaneous Injections in Previously Treated Patients With Chronic Lymphocytic Leukemia Start of enrollment: 2002 Oct 01
- FCR Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic Leukemia Start of enrollment: 2006 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- Hyper-CVAD and Sequential Blinatumomab Without and With Inotuzumab in Young Adults With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leu...Hagop Kantarjian, Nicholas J Short, Nitin Jain, Fadi G Haddad, Tapan Kadia
American Journal of Hematology. 2025-01-05 - 1 citationsLong-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia.Wei-Ying Jen, Jennifer Marvin-Peek, Hagop M Kantarjian, Yesid Alvarado, Gautam Borthakur
Cancer. 2025-01-01 - 1 citationsSustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE.Jennifer R Brown, Barbara Eichhorst, Nicole Lamanna, Susan M O'Brien, Constantine S Tam
Blood. 2024-12-26
Authored Content
- L-carnitine and Vitamin B Complex for the Treatment of Pegasparaginase-Induced HyperbilirubinemiaFebruary 2018
- Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA101) (iFCG) Treatment for First-Line Therapy of Patients with CLL with Mutated IGHV and Without Deletion 17pOctober 2017
- The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II TrialOctober 2017
Press Mentions
NCCN Awards Grants to Improve Care for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaDecember 4th, 2024- MD Anderson Research Highlights for September 19, 2024September 19th, 2024
- MRD: Powerful Metric for CLL ResearchApril 5th, 2023
- Join now to see all
Professional Memberships
- Member
